MedTrace Logo

Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

NCT00857285 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2009-07-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

olmesartan medoxomil

olmesartan medoxomil oral tablets, once daily for up to 12 weeks

DRUG

losartan potassium

losartan oral tablets, once daily for up to 12 weeks

Sponsors & Collaborators

  • Daiichi Sankyo Taiwan Ltd.

    collaborator INDUSTRY

  • Daiichi Sankyo

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2003-08-31
Completion
2003-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857285 on ClinicalTrials.gov